论文部分内容阅读
患者中男性34例,女性21例,中数年龄66岁(18～89岁)。33例为高度恶性(高恶),22例为低度恶性(低恶)。An Arbor分期为Ⅰ期6例,Ⅱ期4例,Ⅲ期8例,Ⅳ期37例。43例属B细胞性。4例有结外病变(胃1,甲状腺1,韦氏环2例),8例有骨髓浸润,5例呈白血病血像,13例血细胞数减低。所有高恶组及6例低恶组患者均用过蒽环类药物,仅7例获完全缓期(CR),9例部分缓解(PR),其余39例为难治性。16例复发患者中,复发1次9例,复发2次6例,复发3次1例。从确诊到应用VIM方案治疗的时期低恶组为24个月,高恶组为14个月。VIM方案包括鬼臼乙叉甙
Among the patients, there were 34 males and 21 females. The median age was 66 years (18-89 years). Thirty-three patients were highly malignant (highly malignant) and 22 patients were low-grade (low-evil). An Arbor stage was 6 cases in phase I, 4 cases in stage II, 8 cases in stage III, and 37 cases in stage IV. 43 cases belong to B cell. 4 cases had extranodal lesions (gastric 1, thyroid 1, and 2 cases of Wechsler’s rings), 8 cases had bone marrow infiltration, 5 cases showed leukemia blood, and 13 cases had lower blood cell counts. Anthracyclines were used in all high-risk and 6 low-risk groups. Only 7 patients received complete remission (CR), 9 had partial remission (PR), and the remaining 39 were refractory. Of the 16 patients with recurrence, 9 recurred 1 times, 6 relapsed 2 times, and 1 recurred 3 times. From the time of diagnosis to treatment with the VIM regimen, the low-grade group was 24 months and the high-grade group was 14 months. The VIM solution includes the Ephraim